# Clinical Trials Data ERBB2 - Document 52

# S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

## Clinical Trial: https://clinicaltrials.gov/study/NCT00896727

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of primary invasive adenocarcinoma of the breast\n\n \* Stage I-IIIA disease (T1-3, N0-1, M0)\n\* Enrolled on clinical trial SWOG-9313\n\* Tumor tissue available for testing\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients from SWOG 9313 consented to banking",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided, a patient with an ERBB2 gene mutation would still be eligible for this clinical trial if they meet the following conditions:  
  
1. They have a diagnosis of primary invasive adenocarcinoma of the breast.  
2. They have stage I-IIIA disease (T1-3, N0-1, M0).  
3. They are enrolled in clinical trial SWOG-9313.  
4. Tumor tissue is available for testing.  
5. They are female and at least 18 years old.  
  
There is no mention of excluding patients based on specific genetic mutations such as an ERBB2 mutation, so the mutation status does not affect eligibility unless specified otherwise in additional criteria not provided.